Neuroendocrine Prostate Cancer Subtype Is Aggressive and More Common Than Expected
Elisa Becze BA, ELS, Editor
Voice
Description
Nearly 20% of men with metastatic, castration-resistant prostate cancer had tumors that developed into the treatment-emergent small-cell neuroendocrine (t-SCNC) subtype, which is associated with shorter survival than other subtypes, according to findings from a study published in the Journal of Clinical Oncology.